The Contribution of BRCA1 and BRCA2 to Ovarian Cancer

The Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers

(2009) Yvette Drew et al.   Annals of the New York Academy of Sciences

Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families

(2009) DGR Evans et al.   CLINICAL GENETICS

Targeted therapy for cancer using PARP inhibitors

(2008) Christopher J Lord et al.   CURRENT OPINION IN PHARMACOLOGY

Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21

(2008) Albert Tenesa et al.   NATURE GENETICS

Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer

(2008) Julius Gudmundsson et al.   NATURE GENETICS

Multiple newly identified loci associated with prostate cancer susceptibility

(2008) Rosalind A Eeles et al.   NATURE GENETICS

A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3

(2008) Ian PM Tomlinson et al.   NATURE GENETICS

Effect ofBRCA1/2Mutations on Long-Term Survival of Patients With Invasive Ovarian Cancer: The National Israeli Study of Ovarian Cancer

(2007) Angela Chetrit et al.   JOURNAL OF CLINICAL ONCOLOGY